Drugs / horse anti-thymocyte globulin (ATG)
horse anti-thymocyte globulin (ATG)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT05600426 Comparator | Jan 2023 → Dec 2029 expected | aplastic anemia | Boston Children's Hospital | Active not recruiting | No outcome recorded |
| — | NCT02845596 Comparator | Aug 2016 → Nov 2020 | acquired aplastic anemia | Michael Pulsipher | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | horse anti-thymocyte globulin (ATG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05600426 ↗ |
| Modality | Protein / enzyme biologic | “horse anti-thymocyte globulin (ATG)” NCT02845596 ↗ |